002393.SZ
力生制药
SZSE · Healthcare · C 制造业 · CN
CNY 13.82
−4.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.3B | 1.2B | 1.1B |
| Cost of Revenue | 616.0M | 622.8M | 600.4M | 468.2M | 486.3M |
| Gross Profit | 738.5M | 769.2M | 735.8M | 684.9M | 660.3M |
| Operating Expenses | |||||
| R&D Expense | 104.4M | 115.2M | 126.5M | 105.6M | 106.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 146.9M | 149.8M | 137.8M | 113.6M | 114.5M |
| Selling & Marketing Expense | 342.4M | 374.6M | 367.1M | 318.9M | 336.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 591.6M | 614.6M | 611.2M | 501.4M | 513.2M |
| Cost and Expenses | 1.2B | 1.2B | 1.2B | 969.5M | 999.5M |
| Operating Income (EBIT) | 464.3M | 469.1M | 221.7M | 419.8M | 118.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 450.6M | 455.6M | 215.9M | 420.2M | 118.4M |
| Income Tax Expense | 31.3M | 32.9M | 30.0M | 58.4M | 24.8M |
| Bottom Line | |||||
| Net Income | 412.9M | 416.3M | 184.5M | 361.8M | 93.6M |
| Earnings from Cont. Ops | 419.2M | 422.7M | 186.0M | 361.8M | 93.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 412.9M | 416.3M | 184.5M | 361.8M | 93.6M |
| Per Share | |||||
| Basic EPS | CN¥1.60 | CN¥1.62 | CN¥0.72 | CN¥1.40 | CN¥0.51 |
| Diluted EPS | CN¥1.60 | CN¥1.62 | CN¥0.72 | CN¥1.40 | CN¥0.51 |
| Revenue Per Share | CN¥5.22 | CN¥5.42 | CN¥5.21 | CN¥4.46 | CN¥6.25 |
| Shares | |||||
| Basic Shares Outstanding | 259.4M | 257.0M | 256.3M | 258.4M | 183.5M |
| Diluted Shares Outstanding | 259.4M | 257.0M | 256.3M | 258.4M | 183.5M |
| Profitability Metrics | |||||
| EBITDA | — | 545.1M | 300.0M | 486.2M | 183.3M |
| D&A | — | 76.0M | 78.3M | 66.4M | 65.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026